HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.
April 26, 2024 | 9:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Lisata Therapeutics with a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst like Joseph Pantginis could positively influence investor sentiment towards Lisata Therapeutics, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100